Cargando…
Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron
Granisetron and other 5-hydroxytryptamine type 3 (5-HT(3)) receptor antagonists are first-line agents for preventing chemotherapy-induced nausea and vomiting (CINV). Current treatment guidelines prefer the longer-acting agent, palonosetron, for CINV prevention in some chemotherapy regimens. A new gr...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863535/ https://www.ncbi.nlm.nih.gov/pubmed/27186139 http://dx.doi.org/10.2147/JEP.S68880 |